2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptake
2020
Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption
Dinan MA, Wilson LE, Reed SD, Griggs JJ, Norton EC. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. Clinical Breast Cancer 2020, 20: 487-494.e1. PMID: 32653473, DOI: 10.1016/j.clbc.2020.05.010.Peer-Reviewed Original Research
2015
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. Journal Of Clinical Oncology 2015, 34: 130-138. PMID: 26598755, PMCID: PMC4872005, DOI: 10.1200/jco.2015.63.2489.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlack or African AmericanBreast NeoplasmsClinical Trials, Phase II as TopicConfounding Factors, EpidemiologicErbB ReceptorsFemaleGene Expression ProfilingHealthcare DisparitiesHumansInsurance CoverageLymphatic MetastasisMiddle AgedMolecular Targeted TherapyNeoplasm StagingNorth CarolinaPoisson DistributionPractice Guidelines as TopicPrecision MedicinePredictive Value of TestsResearch DesignRisk AssessmentRisk FactorsConceptsNode-positive breast cancerNon-black womenODX testingNode-negative patientsBreast cancerOncotype DXBlack patientsRacial disparitiesEarly-stage breast cancerCarolina Breast Cancer StudyGuideline-concordant careNode-positive patientsCancer care qualityPopulation-based studyOncotype DX testingQuality of careNorth Carolina womenLow socioeconomic statusMedium tumor sizeBlack womenBreast Cancer StudyAdjuvant chemotherapyMore comorbiditiesConcordant careTumor sizeAssociation Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenetic TestingGuideline AdherenceHumansInsurance BenefitsMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPatient SelectionPhenotypePractice Guidelines as TopicPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsReceipt of chemotherapyLower chemotherapy useHigh-risk diseasePatients 70 yearsChemotherapy useBreast cancerRecurrence scoreMedicare beneficiariesNational Comprehensive Cancer Network guidelinesEarly-stage breast cancerConsideration of chemotherapyLow-risk diseaseOverall chemotherapy useIncident breast cancerLow-risk patientsRetrospective cohort studyHigh-risk patientsPrespecified subgroup analysisUse of chemotherapyAdditional prognostic informationEnd Results (SEER) dataInvasive breast cancerRS assayNCCN riskAdjuvant chemotherapyInitial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology 2015, 1: 158-166. PMID: 26181015, DOI: 10.1001/jamaoncol.2015.43.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGuideline AdherenceHealthcare DisparitiesHumansMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypePractice Guidelines as TopicPractice Patterns, Physicians'Predictive Value of TestsRacial GroupsResidence CharacteristicsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsIntermediate-risk diseaseBreast cancerRecurrence scoreClinical practiceNode-negative breast cancerNational Comprehensive Cancer NetworkAdjuvant chemotherapy useIncident breast cancerComprehensive Cancer NetworkEnd Results (SEER) dataHigh-grade diseaseRetrospective observational studyRoutine clinical practiceTumor histologic characteristicsMedicare coverage decisionsAdjuvant chemotherapyChemotherapy useN1 diseaseMost patientsComorbid conditionsMultivariable analysisRS assayClinical variablesStudy criteriaBlack race
2014
Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass
Havrilesky LJ, Dinan M, Sfakianos GP, Curtis LH, Barnett JC, Van Gorp T, Myers ER. Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. Journal Of The National Cancer Institute 2014, 107: dju322. PMID: 25515232, DOI: 10.1093/jnci/dju322.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlgorithmsBiomarkers, TumorCA-125 AntigenCost-Benefit AnalysisDecision MakingDisease ManagementFemaleGenital Neoplasms, FemaleHumansMaleMarkov ChainsMedicareMembrane ProteinsMiddle AgedPostmenopausePractice Guidelines as TopicPremenopauseReferral and ConsultationRisk AssessmentSEER ProgramSensitivity and SpecificityUnited StatesWorkloadConceptsPostmenopausal womenAdnexal massesCutoff valueEnd Results-MedicareState Inpatient DatabasesGynecologists guidelinesBiomarker validation studiesPremenopausal womenClinical outcomesGynecologic oncologistsInpatient DatabaseMalignancy AlgorithmSurgical volumeReferral strategiesTriage strategiesMedical costsRelative survivalPhysician workloadCA125Test characteristicsCost-effective strategyWomenTest sensitivityAmerican CongressMedicare reimbursement
2013
Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis. Journal Of Clinical Oncology 2013, 31: 4188-4198. PMID: 24145348, DOI: 10.1200/jco.2013.48.9021.Peer-Reviewed Original ResearchMeSH KeywordsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsContraceptives, OralFemaleHeterozygoteHumansMutationOvarian NeoplasmsRisk AssessmentConceptsBRCA1/2 mutation carriersBRCA2 mutation carriersOvarian cancerBreast cancerMutation carriersFamily historyOC useCancer riskSystematic reviewOral contraceptive useHigh-risk womenUse of OCsBreast cancer riskOvarian cancer riskStrong family historyTiming of useOral contraceptivesCochrane DatabaseInverse associationBRCA1/2 mutationsContraceptive useElevated riskGeneral populationUnique citationsMeta-AnalysisRisk of Acute Thromboembolic Events With Oral Contraceptive Use
Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, Hasselblad V, Sanders GD, Myers ER. Risk of Acute Thromboembolic Events With Oral Contraceptive Use. Obstetrics And Gynecology 2013, 122: 380-389. PMID: 23969809, DOI: 10.1097/aog.0b013e3182994c43.Peer-Reviewed Original ResearchMeSH KeywordsContraceptives, Oral, HormonalFemaleHumansMyocardial InfarctionRisk AssessmentStrokeVenous ThromboembolismConceptsOral contraceptive pillsVenous thromboembolismMyocardial infarctionIschemic strokeHemorrhagic strokeOdds ratioCombined oral contraceptive pillAcute thromboembolic eventsOral contraceptive useRandomized clinical trialsSummary odds ratiosThromboembolic eventsCochrane DatabaseContraceptive pillsOCP useOCP usersClinical trialsSTUDY SELECTIONInclusion criteriaContraceptive useThromboembolismDiscordant decisionsSystematic reviewStrokeTeam review